A Study of an Investigational Treatment in Patients With Bacteremia and Endocarditis

Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!

Open to people ages 18-90

• Age of 18 to 90 years
• Index blood culture collection within 96 hours prior to enrollment positive for S. aureus
• Experienced at least one sign or symptom related to SAB within past 96 hours prior to enrollment
• Known or suspected left- and/or right-sided endocarditis by modified Duke criteria and/or known or suspected complicated SAB
• Required duration of SOC antibiotic therapy ≤ 42 days

• Previous receipt of LSVT-1701 or CF-301 (exebacase)
• Known hypersensitivity to kanamycin or other aminoglycosides
• Treatment with any potentially effective (anti-S. aureus) systemic antibiotic for > 96 hours within 7 days before enrollment. Exception: Persistent S. aureus bacteremia after 96 hours of prior appropriate systemic antistaphylococcal antibiotic, and/or resistance to the prior systemic antibiotic
• Treatment with dalbavancin or oritavancin within the previous 90 days
• Known or suspected brain abscess or meningitis
• Community acquired pneumonia, nosocomial pneumonia because of pathogens other than
  1. aureus, or known polymicrobial bacteremia
• Presence of an intravascular infection source or extravascular material that cannot be removed within 96 hours after enrollment